Although the development of specific LSD1 inhibitors is still in its infancy, three agents (tranylcypromine, GSK2879552 and ORY-100) are currently undergoing clinical evaluation, primarily in AML patients (Table 1). Here, KDM1A is linked to acute myeloid leukemia.